However, this is an opportunity for companies to invest in preventive health and a robust pharmaceutical sector to address this market. Norbert Hültenschmidt, director and head, healthcare practice – Europe, Middle East and Asia (EMEA) at Bain & Co, spoke about opportunities for Indian pharmaceutical companies in domestic and international markets, why pipeline for patented drugs is drying up globally and which areas Indian pharmaceutical companies are targeting for drug development.
